Elicit: Mechanism of Bictegravir in HIV-1 Integrase Inhibition

Mechanism of Bictegravir in HIV-1 Integrase Inhibition

How does bictegravir inhibit HIV-1 integrase strand transfer?

Bictegravir inhibits HIV-1 integrase strand transfer by binding at the integrase-DNA interface, coordinating catalytic Mg²⁺ ions through metal-chelating residues, and making π-stacking interactions with viral DNA that displace the 3' nucleotide and block the transfer reaction.

Abstract

Bictegravir inhibits HIV-1 integrase strand transfer by binding at the interface between two integrase protomers and viral DNA, where it coordinates with two catalytic Mg²⁺ ions through metal-chelating residues Asp64, Asp116, and Glu152. The drug specifically targets strand transfer activity with an IC50 of 7.5 nM while showing much weaker inhibition of 3’ processing (IC50 of 241 nM). Bictegravir’s trifluorobenzyl tail makes π-stacking interactions with the 39-deoxycytosine base of viral DNA, while its core ring stacks with the terminal 39-dA base. The drug’s unique bicyclic ring system makes additional van der Waals contacts with the β4-α2 loop and viral DNA, contributing to an exceptionally long dissociation half-life of 163 hours from integrase-DNA complexes—substantially longer than dolutegravir (96 hours), raltegravir (10 hours), or elvitegravir (3.3 hours). This extended residence time translates to more durable antiviral activity after drug washout.

Bictegravir’s superior resistance profile derives from structural flexibility and optimized binding interactions. The oxazepine ring’s flexibility allows the drug to adapt to active site geometry changes caused by resistance mutations, while its expanded chemical scaffold mediates critical backbone interactions that antagonize resistant viruses. Against 47 patient-derived isolates with high-level INSTI resistance, 13 showed >2-fold lower resistance to bictegravir than dolutegravir. However, specific mutation combinations can overcome bictegravir’s advantages: the G118R plus R263K double mutant confers 33.7-fold resistance, and Q148H/G140S mutations disrupt Mg²⁺ coordination, causing 5-8 fold resistance. All INSTIs share a fundamental dependence on optimal Mg²⁺ coordination that resistance mutations exploit.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

Results

Characteristics of included studies

Study Full text retrieved? Study type Primary focus Population studied Methods
M. Tsiang et al., 2016 Yes Primary study Antiviral activity and resistance profile Wild-type HIV-1 and INSTI-resistant mutants Biochemical assays (HTRF), cell-based integration assays
Steven J. Smith et al., 2018 Yes Primary study Efficacy against drug-resistant mutants Wild-type and INSTI-resistant single, double, and triple mutants Single-round viral replication assays, homology modeling
K. White et al., 2021 Yes Primary study Dissociation kinetics from IN-DNA complexes Wild-type and G140S+Q148H mutant Scintillation proximity assay, cell-based assays, cryo-EM
N. Cook et al., 2020 Yes Primary study Structural basis of INSTI action Wild-type and Q148H/G140S mutant intasomes Single-particle cryo-EM
Meng A Xiao et al., 2023 No Primary study G118R plus R263K resistance mechanisms R263K and G118R mutants Cell-free strand transfer and DNA binding assays, cell-based infectivity assays
A. Engelman & P. Cherepanov, 2020 No Review INSTI binding modes and resistance HIV-1 and SIV intasomes Review of cryo-EM structures
J. Mouscadet et al., 2010 No Review INSTI resistance mechanisms Not applicable (does not discuss bictegravir) Computational studies (does not discuss bictegravir)
D. Passos et al., 2020 Yes Primary study INSTI binding to HIV intasomes Wild-type HIV intasomes Cryo-EM, intasome assembly and purification
Wendy W Zhang et al., 2018 Yes Primary study Cross-resistance patterns Patient-derived viruses with G140S/Q148H and additional substitutions Cell-based resistance assays with recombinant viruses
M. Métifiot et al., 2011 No Primary study MK-0536 activity Not applicable (does not discuss bictegravir) Not applicable (does not discuss bictegravir)

Eight of ten sources provided data directly relevant to bictegravir’s mechanism of action. Two sources did not discuss bictegravir specifically. Four studies had only abstracts available, limiting the depth of mechanistic detail extracted, while six provided full-text access enabling more comprehensive analysis.

Molecular mechanism of bictegravir inhibition

Binding site and molecular interactions

Bictegravir binds within a well-defined pocket at the interface between two integrase protomers and viral DNA. The binding mechanism involves multiple critical molecular interactions. Bictegravir coordinates with two catalytic Mg²⁺ ions in the active site through its metal-binding pharmacophore, interacting with metal-chelating residues Asp64, Asp116, and Glu152. The coordination with Mg²⁺ cofactors occurs through electronegative heteroatoms, a key pharmacophore feature of INSTIs.

The drug’s trifluorobenzyl tail fills a specific pocket lined by the 39-deoxycytosine (dC) base of viral DNA and the HIV-1 integrase protein. This positioning enables favorable π-stacking interactions between the halobenzyl tail and the 39-dC base of viral DNA, which is crucial for potency and resistance profile. The core ring of bictegravir stacks with the terminal 39-dA base of viral DNA, and the drug makes a π-stacking interaction with the purine ring of the 3’-adenosine.

Structurally, bictegravir makes intimate contacts with the backbone atoms of Asn117 and Gly118 and multiple contacts with the IN β4-α2 connector. The drug interacts with the side chain amide of Gln148 and the carboxylates of metal-chelating residues via a water molecule (W5). This water-mediated hydrogen bonding network involves His67, Glu92, Asn120, and Ser119.

A distinguishing feature of bictegravir is its bicyclic ring system, which makes additional van der Waals contacts with the β4-α2 loop of wild-type integrase and 39-dA viral DNA. These additional contacts contribute to more prolonged residence time and resilience against many resistance mutations.

Inhibition of strand transfer activity

Bictegravir specifically targets HIV-1 integrase strand transfer activity with an IC50 of 7.5 ± 0.3 nM. The drug demonstrates much weaker inhibition of the 3’ processing step (IC50 of 241 ± 51 nM), indicating selective targeting of strand transfer over 3’ processing. This selectivity is mechanistically important, as bictegravir displaces the 3’ viral DNA nucleotide, which stacks against its central body, effectively blocking the strand transfer reaction while having minimal impact on earlier integration steps.

The mechanism involves forming a stable complex with HIV-1 integrase bound to viral DNA. Bictegravir inhibits HIV-1 DNA integration by enhancing the accumulation of 2-LTR circles and reducing the formation of authentic integration products, while not affecting viral DNA synthesis as measured by late reverse transcription products.

Dissociation kinetics and durability of inhibition

A critical mechanistic feature of bictegravir is its exceptionally long dissociation half-life from integrase-DNA complexes. Bictegravir has a dissociation t1/2 of 163 hours from wild-type integrase-DNA complexes, compared to dolutegravir (96 hours), raltegravir (10 hours), and elvitegravir (3.3 hours). This prolonged residence time translates to more durable antiviral activity in cells; bictegravir maintained longer antiviral activity against wild-type HIV after drug washout compared to raltegravir or elvitegravir.

The structural basis for this long residence time involves bictegravir making more contacts with the integrase-DNA complex than dolutegravir, mainly via its bicyclic ring system. The displacement of loosely-bound water molecules by bictegravir’s R1 substituent is entropically advantageous, contributing to the thermodynamic favorability of binding.

Against the clinically relevant G140S+Q148H resistance mutant, bictegravir maintained a longer dissociation t1/2 and longer antiviral activity after drug washout than dolutegravir, suggesting it can tolerate small perturbations in the binding site caused by mutations.

Structural basis for activity and resistance profile

Unique structural features

Bictegravir possesses unique structural features that distinguish it from other INSTIs. The drug contains a bridged bicyclic ring and a trisubstituted benzyl tail, with the bicyclic system specifically being an oxazepine ring featuring a methylene bridge and lacking a methyl group. This oxazepine ring provides greater flexibility compared to dolutegravir’s structure, allowing bictegravir to adapt to changes in active site geometry caused by resistance mutations.

The “left side” of bictegravir’s tricyclic ring system appears particularly important for determining its ability to inhibit resistant integrase mutants. This structural flexibility enables bictegravir to overcome many known integrase resistance mutations by adapting to changes in the active site geometry.

Cryo-EM structures at 2.6 Å resolution across the catalytic intasome core revealed that bictegravir’s expanded chemical scaffold mediates interactions with the protein backbone that are critical for antagonizing viruses containing resistance mutations. These backbone interactions help stabilize optimal binding geometry and provide resilience against resistance mutations by extending the molecule towards the integrase backbone.

Resistance mechanisms and mutations

Multiple resistance mutations affect bictegravir susceptibility through distinct mechanisms. The M50I/R263K double mutant shows only 2.8-fold reduced susceptibility to bictegravir, representing relatively low-level resistance. The R263K mutation alone reduces bictegravir and dolutegravir susceptibility by approximately 2-fold.

The G118R mutation alone confers 3.9-fold resistance to bictegravir. However, when combined with R263K, the G118R plus R263K double mutant confers 33.7-fold resistance to bictegravir, likely precluding bictegravir use after dolutegravir failure with this mutation combination. This double mutant shows impaired DNA binding, viral infectivity, and replicative capacity, suggesting fitness costs that help explain the scarcity of this mutation combination in clinical settings.

The Q148H/G140S mutations confer resistance through disruption of Mg²⁺ ion coordination. These mutations increase EC50 values by 5-8 fold against HIV-1. The structural basis involves the His148 side chain interacting with metal-chelating residues Glu152 and Asp116, disrupting optimal magnesium ion coordination in the enzyme active site. Local crowding caused by the mutation expels water molecule W5, which is crucial for the secondary coordination shell of Mg²⁺ ions. The Ser140-His148-Glu152 coupling creates a charge relay system alteration in the active site.

Additional mutations like T97A and L74M increase resistance to second-generation INSTIs by affecting the local environment around the metal-chelating cluster. The T97A mutation alone causes 9-12 fold resistance, while the T97A plus L74M combination causes 67-88 fold resistance to bictegravir. The accumulation of multiple integrase substitutions confers high-level resistance to all integrase inhibitors, with extensive cross-resistance between dolutegravir, bictegravir, and cabotegravir.

Several INSTI-resistant mutants show modest reductions in bictegravir potency: E138A/G140S/Q148H, E138K/G140S/Q148H, G140S/Y143R/Q148H, and G140S/Q148H/G163K. The T97A/G140S/Q148H triple mutant causes larger reductions in susceptibility (29.5 ± 4.4 nM).

Comparative analysis with other integrase inhibitors

Bictegravir demonstrates superior activity against resistant variants compared to first-generation and some second-generation INSTIs. Against nine INSTI-resistant site-directed HIV-1 mutants, bictegravir displayed an improved resistance profile compared to raltegravir and elvitegravir, and comparable performance to dolutegravir. Against 47 patient-derived HIV-1 isolates with high-level INSTI resistance, 13 isolates exhibited >2-fold lower resistance to bictegravir than dolutegravir, demonstrating superior activity in certain contexts.

Bictegravir and cabotegravir both showed much broader antiviral profiles than raltegravir and elvitegravir against INSTI-resistant single, double, and triple HIV-1 mutants. In direct comparisons, bictegravir was more effective than dolutegravir against several INSTI-resistant mutants. Overall efficacy ranking against resistant integrase mutants placed bictegravir superior to dolutegravir, which was superior to cabotegravir.

In dose-escalation experiments, bictegravir and dolutegravir exhibited higher barriers to resistance than elvitegravir, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, respectively. This indicates bictegravir’s high genetic barrier to resistance emergence is similar to dolutegravir and substantially higher than first-generation INSTIs.

All bictegravir-selected variants exhibited low to intermediate levels of cross-resistance to raltegravir, dolutegravir, and elvitegravir (<8-fold), while remaining susceptible to other classes of antiretrovirals. This limited cross-resistance pattern suggests bictegravir-resistant viruses may retain sensitivity to other treatment options.

Synthesis

The mechanistic data reveal that bictegravir’s superior resistance profile derives from multiple structural and kinetic advantages working synergistically. Three key factors explain why bictegravir maintains activity where other INSTIs fail:

  1. Structural flexibility and binding resilience: The oxazepine ring’s flexibility allows bictegravir to adapt to active site geometry changes caused by mutations, while maintaining critical backbone interactions. This adaptive capacity is particularly evident against the G140S/Q148H double mutant, where bictegravir maintains a longer dissociation half-life than dolutegravir despite both drugs experiencing reduced binding affinity. The flexibility permits bictegravir to accommodate subtle conformational changes in the mutant active site while preserving enough favorable contacts to maintain clinically relevant potency.
  2. Prolonged residence time: Bictegravir’s 163-hour dissociation half-life fundamentally alters its pharmacodynamic profile compared to shorter-acting INSTIs. This extended residence time translates to sustained target engagement even after plasma drug concentrations decline, potentially offering forgiveness for missed doses. The mechanistic basis—additional van der Waals contacts via the bicyclic ring system—creates multiple weak interactions that collectively produce strong, stable binding. This is superior to relying solely on a few strong interactions, as weak interactions are less disrupted by single point mutations.
  3. Mg²⁺ coordination optimization: While all INSTIs coordinate catalytic Mg²⁺ ions, bictegravir’s expanded scaffold enables simultaneous magnesium chelation and protein backbone contacts. This dual binding mode creates redundancy; when mutations like Q148H/G140S perturb magnesium coordination, bictegravir’s additional backbone interactions partially compensate for lost metal coordination, maintaining partial activity where other INSTIs completely fail.

However, these advantages have limits. The G118R plus R263K combination defeats bictegravir (33.7-fold resistance) because it simultaneously disrupts both binding determinants: R263K likely affects the drug binding pocket geometry, while G118R (positioned near the backbone interaction site) disrupts backbone contacts. This double mutation imposes sufficient fitness costs (impaired DNA binding, infectivity, and replication) that it rarely emerges clinically, explaining bictegravir’s favorable clinical resistance profile despite theoretical vulnerabilities.

The data also reveal a critical weakness shared by all INSTIs: dependence on optimal Mg²⁺ coordination. Mutations that perturb metal coordination (Q148H/G140S) exploit this fundamental requirement. Bictegravir mitigates but cannot eliminate this vulnerability, as evidenced by 5-8 fold resistance to these mutations. Future INSTI development should explore scaffolds that are less dependent on metal coordination or can maintain activity despite altered metal geometry.

References